Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 51-54

  Inoue, A ^a   Saijo, Y ^a,b   Kikuchi, T ^a   Gomi, K ^a   Suzuki, T ^a   Maemondo, M ^a   Miki, M ^b   Sato, T ^c   Nukiwa, T ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Sendai Red Cross Hospital   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboplatin; Chemotherapy; Hemodialysis; Pharmacokinetics; Small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DEXAMETHASONE; ERYTHROPOIETIN; ETOPOSIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CHRONIC KIDNEY FAILURE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LUNG SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0942287954     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh008     Document Type: Article

References (14)

1. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99.
4. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
5. Yanagawa H, Takishita Y, Bando H et al. Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Res 1996; 16: 533-535.
6. LeRoy AF, Wehling ML, Sponseller HL et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochemical Med 1977; 18: 184-191.
7. Allen LM. Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D-glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci 1980; 69: 1440-1441.
8. Shigeyuki O, Sakakibara T, Mase H et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 1988; 28: 208-215.
9. D'Incalci M, Farina P, Sessa C et al. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982; 7: 141-145.
10. Motzer RJ, Niedzwiecki D, Isaacs M et al. Carboplatin-based chemotherapy with parmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 1990; 27: 234-238.
11. Chatelut E, Rostaing L, Gualano V et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 1994; 66: 157-161.
12. Suzuki S, Koide M, Sakamoto S et al. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transplant 1997; 12: 137-140.
13. Watanabe M, Aoki Y, Tomita M et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 2002; 84: 335-338.
14. Watanabe R, Takiguchi Y, Moriya T et al. Feasibility of combination chemotherapy with cisplatin and etoposide for hemodialysis patients with lung cancer. Br J Cancer 2003; 88: 25-30.